IN-VIVO DELIVERY of Smart Receptors for Next-Gen Cell & GENE Therapies

Unlock safe, potent, affordable treatments for oncology, autoimmunity, and fibrosis—
powered by our AI protein design engine.

Introducing MARC: Modular Actuation Receptor Cells

Synthetic immune receptors with best-in-class efficacy and safety, adapted for diverse cell types.

Safe, persistent, potent.

In-VIVO DELIVERY WITH the Modular Vector (MoVE) platform

Immune cell-specific vectors

for in vivo MARC delivery and

activation of T cells, NK cells

and more.

Scalable, off-the-shelf cell therapy made accessible.

BACKED BY PEER-REVIEWED SCIENCE

Tual et al. MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence. Published in JITC, 2025

Link to publication

Investors & Partners

COLLABORATE WITH US!

Contact us to explore opportunities for collaboration

Contact us

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept